Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Raevens has nothing to disclose. Conflict of interest: Dr. Rogiers has nothing to disclose. Conflict of interest: Dr. Geerts has nothing to disclose. Conflict of interest: Dr. Verhelst has nothing to disclose. Conflict of interest: Dr. Samuel has nothing to disclose. Conflict of interest: Dr. van Rosmalen has nothing to disclose. Conflict of interest: Dr. Berlakovich has nothing to disclose. Conflict of interest: Dr. Delwaide has nothing to disclose. Conflict of interest: Dr. Detry has nothing to disclose. Conflict of interest: Dr. Lehner has nothing to disclose. Conflict of interest: Dr. Mittler has nothing to disclose. Conflict of interest: Dr. Nadalin has nothing to disclose. Conflict of interest: Dr. Nevens reports grants from Roche, grants from Astellas, grants from Sandoz, grants and other from BMS, grants and other from CAF, grants and other from MSD, grants and other from TwinPharma, grants and other from Ipsen, other from Gilead, other from Novartis, other from Abbvie, other from Promethera Biosciences, other from Durect, other from Ferring, other from Gore, other from Cook medical, other from Biotest, other from Intercept, outside the submitted work. Conflict of interest: Dr. Pirenne has nothing to disclose. Conflict of interest: Dr. Saner has nothing to disclose. Conflict of interest: Dr. Schneeberger reports other from Merck, other from Astellas, grants and other from Chiesi, other from Teva, other from Novartis, grants from Sandoz, outside the submitted work. Conflict of interest: Dr. Stippel has nothing to disclose. Conflict of interest: Dr. Zoltan has nothing to disclose. Conflict of interest: Dr. Troisi has nothing to disclose. Conflict of interest: Dr. Van Vlierberghe has nothing to disclose. Conflict of interest: Dr. COLLE reports other from PROMETHERA, outside the submitted work. Conflict of interest: Dr. TURK JEROVSEK has nothing to disclose.